Selecta Biosciences (SELB) is scheduled to report 2nd quarter earnings on 08/10/2023.
Regarding Q2 estimates, Wall Street analysts expect Selecta Biosciences to post earnings of -$0.08 per share. Revenue expectations are pegged at $11.09 million. Last quarter, Selecta Biosciences missed earnings estimates, reporting EPS of -$0.14 on estimates of -$0.09. The stock fell by -6.96% the day after the last earnings release.
Year-to-date, SELB stock has fallen by -5.22%.
About Selecta Biosciences
Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. it produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation. The firm proprietary pipeline includes SVP-enabled enzyme, oncology and gene therapies. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian in 2007 and is headquartered in Watertown, MA.
Stay up-to-date on earnings this week, with TipRanks’ Earnings Calendar.
